Stephen Schuster: Mosunetuzumab Leads to Durable Complete Remissions in Non-Hodgkin Lymphoma
Patients with both indolent and aggressive non-Hodgkin lymphomas responded to treatment with the monoclonal antibody, even those whose disease had not responded to CAR...
Patrick Brown: Is Blinatumomab a New Standard of Care for Young Patients With B-Cell...
Patrick A. Brown, MD, discusses the results seen with blinatumomab as consolidation therapy in young patients with higher-risk, relapsed B-cell acute lymphocytic leukemia, where...
Megan Brown: Improving VWD Testing in Girls With Heavy Menstrual Bleeding
Megan C. Brown, MD, describes results from an emergency department–based initiative to improve the diagnostic accuracy of testing for von Willebrand disease in adolescents...
Rajat Bannerji: REGN1979 Active Across Non-Hodgkin Lymphoma Subtypes
The bispecific antibody REGN1979 demonstrated efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no observed dose-limiting toxicities. Rajat Bannerji, MD, PhD,...
Luciano Costa: CC-93269 Shows Clinical Activity in Previously Treated Myeloma
Luciano J. Costa, MD, PhD, shares results from a first-in-human trial of CC-93269, a bispecific antibody that targets B-cell maturation antigen and CD3 T...
Deepu Madduri: An Emerging CAR T-Cell Therapy for Myeloma
Deepu Madduri, MD, discusses findings from the CARTITUDE-1 trial, in which the new CAR T-cell therapy candidate led to a 100% response rate and...
Uma Borate: Evaluating MBG453 in High-Risk MDS and AML
Combining MBG453 with hypomethylating agents was "extremely well tolerated," with no high-grade immune-related toxicities. Uma Borate, MD, discusses the safety and preliminary efficacy data.
David Steensma: Examining H3B-8800 for Myeloid Neoplasms
David Steensma, MD, discusses the results and unanswered questions raised by the first-in-human trial of the splicing modulator in patients with acute myeloid leukemia,...
Aaron Gerds: What Does the Future Hold for Pacritinib?
Aaron Gerds, MD, MS, shares results from the PAC203 trial, which enrolled patients with high-risk and heavily refractory myelofibrosis.
Pulling Back the Curtain: Robert A. Kyle, MD
In more from our interview with Robert A. Kyle, MD, he discusses his early decision to specialize in hematology and looks back on 70 years...
Current Issue
October 2020 Volume 6, Issue 12
This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.